Product logins

Find logins to all Clarivate products below.


In 2017, branded biologic sales in oncology, immunology, endocrinology, and nephrology across the major markets exceeded $80 billion. Sales from biosimilars in the
same therapy areas and regions totaled approximately $2.5 billion. Throughout our 2017-2027 forecast period, increasing numbers of branded biologics are set to lose 
patent protection, with biosimilars expected to enter the market and erode both patient share and drug prices. We present our forecasts for key reference brands and
their biosimilars by therapeutic area, molecule, and region.

Related Market Assessment Reports

Report
Biosimilars – Current Treatment – Ophthalmology
The ophthalmology market is relatively new in the field of biosimilars: Samsung Bioepis / Biogen’s ranibizumab biosimilar, Byooviz, was the first MAb biosimilar to launch in the U.S. market in…
Report
Biosimilars – Current Treatment – Oncology
In 2019, Amgen / Allergan’s trastuzumab biosimilar Kanjinti and bevacizumab biosimilar Mvasi were the first monoclonal antibody (MAb) biosimilars launched in the United States, followed by…
Report
Biosimilars – Current Treatment – Immunology
Biologics approved to treat immune indications (e.g., rheumatoid arthritis, Crohn’s disease) are among the most commercially successful biopharmaceutical products and offer a great opportunity to…
Report
Biosimilars – Emerging Biosimilars – Emerging Biosimilars Landscape
The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 722 currently available and novel biosimilar products, detailing…
Report
Biosimilars – Forecast – Ophthalmology
In 2023, sales of branded biologics in ophthalmology exceeded $9.2 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2023-2033 forecast period…